Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Investor Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: TSX plunges as oil drops
Canada’s main stock index closed out the week in the red on Friday in a broad decline. Energy and miners led the selloff among sectors as reduced demand saw commodities dropped while concerns are... read article.

Recent News

A little surprised with AGN.c (a clinical stage Canadian pharmaceutical development company) AGNPF ‘s action as of late considering their recent news. Especially the announcement that they filed a...read more

Dundee Closes Privatization of Big River Gold With Aura Minerals to Develop & Participate in Future Cash Flows

Jonathan Goodman, CEO “I am pleased to announce the closing of this transaction & for Dundee to participate directly in any future cash flows of this high-quality, development stage mining project in Brazil" ...read more
The Market Herald’s Weekly Cannabis Report – Sept 23, 2022
Cannara Biotech (TSXV:LOVE) has entered British Columbia’s marketplace and has launched its first two premium products in the vape and accessory categories.Cannara’s President and Chief... read article.

buy Adderall online without Prescription Door To Door Delive

can I buy Adderall online without a prescription? If you also searching for a way to buy Adderall online without a prescription so you can take the help of yahoo, google, and search engine. There...read more

Webinar w $AGN CEO Chris Moreau - Tue Sep 27 @ 12:30PM ET

Webinar - Algernon Pharmaceuticals $AGN w/ CEO Chris Moreau Tue, September 27 at 12:30pm ET / 9:30am PT Q&A with Radius Research  Register Here - https://us02web.zoom.us/webinar...read more

Orphan designation would literally be the biggest catalyst

Imagine if Algernon receives the orphan designation for Ifenprodil. Orphan designation is literally one of the strongest possible catalysts for any biotech stock due to its potential 7-year...read more
Buzz on the Bullboards: Cooler days doesn’t mean cooler markets
The autumn season officially starts today and the business world along with the Bullboards have certainly picked up in activity.Every week we track the most-viewed Bullboards in each sector and... read article.

New Press Release - Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recently received a cash payment...read article.

Thematica Insights Report & Investor Guide

Winter is coming – investing in a recession

An investor's guide to understanding investment opportunities ahead of a recession. Click here to access the report.

AGN

Yesterday $AGN filed a request for orphan designation with the FDA for Ifenprodil as a treatment for IPF (chronic lung condition)   following positive results earlier this month from full...read more

New Press Release - Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has decided to advance its investigation of NP...read article.

Lots of Potential for the DMT Phase 1 Trial

Algernon has had a lot of recent news/study results come out from the promising chronic cough and IPF study. However, they're also researching drug repurposing for a number of other diseases as...read more

AGN's DMT study for treating stroke

Algernon Pharmaceuticals Inc. (AGN.c AGNPF) received approval to conduct a clinical study on treating stroke with DMT.  The first part of AGN's study will try to identify a safe non...read more

Algernon Pharmaceuticals AGN AGN.CA 💊💊

Algernon Pharmaceuticals is increasing studies and getting closer to having Ifenprodil on the market for treatment of Chronic idiopathic pulmonary fibrosis       rate and reply

AGN conducting phase 1 study of DMT

AGN announced yesterday that they've received approval to conduct a phase 1 study of an IVF of AP-188 (DMT) for treatment of stroke in the Netherlands from BEBO. While multiple studies have...read more

Breakdown for AGN's latest clinical study approval

Today Algernon Pharmaceuticals Inc. (AGN.c AGNPF) announced that it has received approval to conduct a Phase 1 clinical study of an IVF of DMT for the treatment of stroke. AGN plans to dose the first...read more

New Press Release - Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received approval to conduct a Phase 1...read article.

AGN.c up 77% over the past month

AGN.c announced that they will be the headline sponsor for Wonderland, which is the world-leading academic business gathering for the psychedelic medicine industry. Wonderland will be held from Nov 3 ...read more

AGN CEO discusses positive results in new interview!

ICYMI - Algernon Pharmaceuticals recently reported positive results from their complete data set of its phase 2a study of Ifenprodil for treating idiopathic pulmonary fibrosis (IPF) and chronic cough...read more

New Press Release - Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor

Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland, the world...read article.

New Press Release - Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that it will be the Headline Sponsor for...read article.

AGN.c featured on The Market Herald after sucessful study

The Market Herald recently featured Algernon Pharmaceuticals (AGN.c AGNPF) in 'The Power Play' after the biotech company reported positive drug study results. Its Phase 2a Study evaluating...read more

Algernon Pharmaceuticals AGN.CA 👨🏻‍⚕️👩🏽‍⚕️💊💊

Algernon Pharmaceuticals is making great headway with its' new drug Ifenprodil for treatment of Pulmonary Fibrosis  rate and reply

AGN AGN.ca 👩🏽‍⚕️👨🏻‍⚕️👀👀

https://algernonpharmaceuticals.com/medicalgold-ca-algernon-rapidly-advances-clinical-trials-for-two-lead-programs/ Algernon Pharmaceuticals is employing drug repurposing strategies to test...read more
The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

follow C.AGN on

PIPELINE TARGETED DISEASES MEDIA MANAGEMENT

Video Q&A With CEO Christopher J. Moreau


Download the latest Investor Presentaion
Download the latest Investor Presentation


Algernon Pharmaceuticals | The Power Play
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

TWITTER


FACEBOOK